Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATR | Q13535 | 1/20 | 0.36 |
| ▸ | PKN1 | Q16512 | 1/20 | 0.35 |
| ▸ | PKN2 | Q16513 | 1/20 | 0.35 |
| ▸ | GSK3B | P49841 | 1/20 | 0.33 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.33 |
| ▸ | LEF1 | Q9UJU2 | 1/20 | 0.32 |
| ▸ | PARP1 | P09874 | 3/20 | 0.32 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.31 |
| ▸ | LCK | P06239 | 1/20 | 0.31 |
| ▸ | HPSE | Q9Y251 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6517653 | 0.93 | GSK3B (0.33) | ATRGSK3BDYRK1APARP1SCN9A | |
| SCHEMBL6513547 | 0.86 | ATR (0.36) | ATRGSK3BDYRK1ASCN9ALCK | |
| SCHEMBL6517644 | 0.80 | GSK3B (0.33) | ATRGSK3BDYRK1ASCN9ALCK | |
| SCHEMBL6511063 | 0.79 | RHEB (0.41) | GSK3BDYRK1ALEF1LCK | |
| SCHEMBL15233333 | 0.77 | BRD4 (0.48) | ATRPKN1PKN2LCK | |
| SCHEMBL6523273 | 0.77 | PKN1 (0.38) | PKN1PKN2PARP1 | |
| SCHEMBL5555380 | 0.75 | PKN1 (0.43) | PKN1PKN2PARP1HPSE | |
| SCHEMBL5561415 | 0.74 | LCK (0.39) | GSK3BDYRK1ASCN9ALCK | |
| SCHEMBL14879051 | 0.72 | LCK (0.48) | LCK | |
| SCHEMBL15233053 | 0.72 | GSK3B (0.35) | GSK3BDYRK1ASCN9ALCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8524899-B2 | Oligopeptide containing fused 6-membered ring forming complexes with double stranded dna; complexes can be used for identification of specific dsDNA sequences, inhibiting gene transcription, therapeutic for inhibiting proliferation of undesired cells or modulation of expression of specific gene | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2013-09-03 | — | — | US | disclosed |
| EP-1599474-B1 | Heterocyclic oligomeric compounds for DNA recognition | CALIFORNIA INST OF TECHN (US) | 2013-04-24 | — | — | EP | disclosed |
| US-20050026174-A1 | Alternative heterocycles for DNA recognition | CALIFORNIA INSTITUTE OF TECHNOLOGY | 2005-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050026174-A1 | Alternative heterocycles for DNA recognition | DDB1, PCNA, DNA2 | ATR 1576/4885PKN1 2736/4885PKN2 2911/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.